Healthcare Services

Adeno-Associated Viral Vectors Market Global Report 2026 Market Outlook 2026–2030 with Major Growth Drivers and Emerging Industry Trends

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Adeno-Associated Viral Vectors Market Between 2026 And 2030?

The adeno-associated viral vectors market size has experienced substantial expansion in recent years. It is forecast to grow from $3.17 billion in 2025 to $3.72 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.6%. This historical growth can be ascribed to elements such as the early establishment of AAV vector platforms, the constrained clinical implementation in rare diseases, the initial regulatory frameworks for gene therapy, escalating research into genetic disorder treatments, and an uptick in funding for preclinical studies.

The adeno-associated viral vectors market is projected for significant expansion in the coming years, reaching $6.65 billion by 2030, driven by a compound annual growth rate (CAGR) of 15.6%. This anticipated growth is primarily due to advancements in capsid engineering and vector design, an increase in commercial gene therapy launches, growing demand for personalized medicine, the broadening of global clinical trials, and an escalation in collaborations between biotechnology and pharmaceutical firms. Key trends expected during this period involve the broadening of adeno-associated viral (AAV)-based gene therapies for uncommon genetic conditions, a surge in investment towards both in vivo and ex vivo gene delivery approaches, an increasing integration of AAV vectors into immunotherapy, a heightened emphasis on clinical and commercial-scale gene therapy initiatives, and improvements in regulatory oversight and standardization for gene therapy products.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Adeno-Associated Viral Vectors Market?

The rising occurrence of genetic disorders is projected to propel the expansion of the adeno-associated viral vectors market in the future. Genetic disorders are conditions that arise from anomalies in an individual’s DNA, leading to physical or developmental impairments. The increasing prevalence of these disorders is attributed to improved diagnostic techniques, heightened awareness, and a higher reproductive age, along with environmental factors and genetic drift. Adeno-associated viral vectors are utilized in gene therapy for genetic disorders, delivering corrective genes into target cells to potentially treat conditions such as muscular dystrophy or cystic fibrosis. For instance, in February 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, congenital diseases caused an estimated 240,000 baby deaths globally within 28 days of birth each year. An additional 170,000 children between the ages of 1 month and 5 years die as a result of congenital diseases. Therefore, the growing prevalence of genetic disorders is a key driver for the adeno-associated viral vectors market.

Which Market Segments Are Examined In The Adeno-Associated Viral Vectors Market Study?

The adeno-associated viral vectors market covered in this report is segmented –

1) By Type Of Therapy: Gene Augmentation, Immunotherapy, Other Type Of Therapies

2) By Type Of Gene Delivery Method Used: Ex Vivo, In Vivo

3) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Areas

4) By Scale Of Operation: Preclinical, Clinical, Commercial

5) By Application Area: Gene Therapy, Cell Therapy, Vaccines

Subsegments:

1) By Gene Augmentation: Inherited Genetic Disorders, Muscular Dystrophy, Cystic Fibrosis, Hemophilia

2) By Immunotherapy: Cancer Immunotherapy, Viral Infections Immunotherapy

3) By Other Types Of Therapies: Gene Editing, RNA Therapy

Which Trends Are Influencing The Adeno-Associated Viral Vectors Market?

Major companies in the adeno-associated viral vectors market are concentrating on providing off-the-shelf availability of replication-capsid plasmid to gain a competitive advantage. Rep/Cap plasmids, commonly used in gene therapy for adeno-associated virus (AAV) vector production, are readily accessible from numerous commercial suppliers addressing molecular biology research demands. For instance, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced an off-the-shelf replication-capsid plasmid range that streamlines AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing lentiviral packaging and AAV Helper plasmid offerings, decreasing manufacturing efforts by as much as 66%. These ready-to-use plasmids undergo batch production with comprehensive documentation, adhering to CMC guidelines and accompanied by a Certification of Analysis (COA) to facilitate IND and Clinical Trial Application (CTA) submissions.

Who Are The Primary Competitors In The Adeno-Associated Viral Vectors Market?

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos Inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc., MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Read the full adeno-associated viral vectors market report here:

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

What Are The Leading Geographic Regions In The Adeno-Associated Viral Vectors Market?

North America was the largest region in the adeno-associated viral vectors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Adeno-Associated Viral Vectors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15969&type=smp

Browse Through More Reports Similar to the Global Adeno-Associated Viral Vectors Market 2026, By The Business Research Company

oral expectorant global market report

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

viral inactivation global market report

https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

viral hepatitis global market report

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795